These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2130003)

  • 41. [A new type of ointment base: investigations on its antimicrobial properties (author's transl)].
    Wewelka G; Gergely T; Koller W
    Wien Klin Wochenschr; 1977 Sep; 89(18):632-4. PubMed ID: 410167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A comparison of the antibacterial activity of sulphonamide-trimethoprim combinations.
    Fourie ED; van Straten AM; Maritz HC; van Rensburg AJ
    S Afr Med J; 1979 Mar; 55(14):544-7. PubMed ID: 377523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model.
    Rustige C; Wiedemann B
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1107-11. PubMed ID: 2118324
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Mechanisms of bacterial resistance to quinolones].
    Yoshida H
    Nihon Saikingaku Zasshi; 1996 Oct; 51(4):973-92. PubMed ID: 8994343
    [No Abstract]   [Full Text] [Related]  

  • 45. [Dynamics of antibiotic resistance of purulent septic pathogens at an emergency facility].
    Men'shikov DD; Evdokimova NV; Grunenkova IV; Astaf'eva RF; Kurilin BL; Men'shikova ED; Lazareva EB; Vasil'ev VA
    Antibiot Khimioter; 2002; 47(8):12-5. PubMed ID: 12515091
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Antibiotic policy and bacterial resistance].
    Snijder JA
    Ned Tijdschr Geneeskd; 1978 Dec; 122(50):1958-62. PubMed ID: 364322
    [No Abstract]   [Full Text] [Related]  

  • 47. [Pharmacodynamic and pharmacokinetic approaches to optimization of lomefloxacin].
    Iakovlev SV
    Antibiot Khimioter; 1998; 43(10):42-5. PubMed ID: 9825110
    [No Abstract]   [Full Text] [Related]  

  • 48. Synthesis of 7-thio-substituted 4-oxoquinoline-3-carboxylic acids with antibacterial activity.
    Nishimura Y; Hirose T; Okada H; Shibamori K; Nakano J; Matsumoto J
    Chem Pharm Bull (Tokyo); 1990 Aug; 38(8):2190-6. PubMed ID: 2126225
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Save the Quinolones! Impact of a Non-Restrictive Fluoroquinolone Reduction Initiative on Antibiotic Use and Resistance at an Urban Teaching Hospital.
    Smoke SM; Plotkin S; Patel N; Hilden P
    J Pharm Pract; 2022 Oct; 35(5):707-710. PubMed ID: 33759616
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of concentration on bactericidal activity of cefotaxime.
    Shah PM; Troche G; Stille W
    J Antimicrob Chemother; 1979 Jul; 5(4):419-22. PubMed ID: 114510
    [No Abstract]   [Full Text] [Related]  

  • 51. Flavone and xanthone derivatives related to fluoroquinolones.
    Mari S; Rossi M; Valenti P; Da Re P
    Farmaco; 1999 Jun; 54(6):411-5. PubMed ID: 10443020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemistry and antibacterial activity of nitrobenzofurans.
    Powers LJ
    J Med Chem; 1976 Jan; 19(1):57-62. PubMed ID: 812994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biliary elimination and hepatic disposition of a new fluoroquinolone, temafloxacin: experimental evaluation.
    Brogard JM; Koechlin C; Westphal JF; Blicklé JF; Dorner M; Jehl F
    Drugs Exp Clin Res; 1990; 16(8):407-16. PubMed ID: 2097145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. United States geographic bacteria susceptibility patterns. 1996 ASCP Susceptibility Testing Group. American Society of Clinical Pathologists.
    Am J Clin Pathol; 1998 Feb; 109(2):144-52. PubMed ID: 9583885
    [No Abstract]   [Full Text] [Related]  

  • 55. In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium.
    Mitsuyama J; Itoh Y; Takahata M; Okamoto S; Yasuda T
    Antimicrob Agents Chemother; 1992 Sep; 36(9):2030-6. PubMed ID: 1329639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Studies on pyridonecarboxylic acids. IV. Synthesis and antibacterial activity evaluation of S-(-)- and R-(+)-6-fluoro-1-methyl-4-oxo-7- (1-piperazinyl)-4H-[1,3] thiazeto[3,2-a]quinoline-3-carboxylic acids.
    Segawa J; Kazuno K; Matsuoka M; Amimoto I; Ozaki M; Matsuda M; Tomii Y; Kitano M; Kise M
    Chem Pharm Bull (Tokyo); 1995 Jul; 43(7):1238-40. PubMed ID: 7586065
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quinolone resistance: an alternative perspective.
    Fish DN; Piscitelli SC; Danziger LH
    Arch Intern Med; 1992 Jun; 152(6):1329-30. PubMed ID: 1301015
    [No Abstract]   [Full Text] [Related]  

  • 58. In vitro susceptibility of mycoplasmas to a new quinolone, BAY Y 3118.
    Renaudin H; Bébéar C
    Drugs; 1995; 49 Suppl 2():243-5. PubMed ID: 8549318
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparative evaluation of herbs and spices against bacterial pathogens.
    Gupta SK; Tshikaya M; Kingston M; Chopra BK
    Dent Implantol Update; 2012 Oct; 23(10):73-9. PubMed ID: 23116004
    [No Abstract]   [Full Text] [Related]  

  • 60. Products from furans. 1. Sunthesis and anticoccidial and antimicrobial activity of 5-amino-5,6-dihydro-6-methoxy-2-methyl-2-(4'-biphenylyl)-2H-pyran-3(4H)-ones and related compounds.
    Georgiadis MP
    J Med Chem; 1976 Feb; 19(2):346-9. PubMed ID: 814239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.